Retatrutide 30mg Pen Refill Vial

Retatrutide is an investigational once-weekly triple-hormone injection (GLP-1, GIP, and glucagon receptor agonist) showing superior weight loss, with phase 2 trials demonstrating up to 24% body weight loss in 48 weeks. It offers significant metabolic benefits, including improved blood sugar control, up to 80% liver fat reduction, and better blood pressure.

Key Benefits of Retatrutide:

•  Significant Weight Loss: Trials showed that at 48 weeks, participants on the highest dose lost an average of 24.2% of their body weight, with some losing over 30%. 
• Triple-Action Metabolism Boost: Unlike dual agonists (like Tirzepatide) or GLP-1s, retatrutide targets GIP, GLP-1, and glucagon receptors. The added glucagon receptor agonism increases energy expenditure (calories burned) alongside reducing appetite. 
• Substantial Fat Reduction: Studies indicated a significant reduction of up to 80% in liver fat by week 24. 
• Improved Metabolic Health: Participants experienced improved glycemic control, lower blood pressure, and improved lipid levels. Over 70% of participants with pre-diabetes returned to normal blood sugar levels. 
• Potential Cardiorenal Protection: Phase 2 data suggested improved kidney function markers, specifically a 31.5% reduction in urinary albumin in some participants. 
• Reduced Cravings: Participants reported reduced snacking, improved control over hunger, and better eating behavior management. Retatrutide is in phase 3 clinical trials, with potential FDA approval anticipated between late 2026 and 2027. 
• Common side effects are generally gastrointestinal—nausea, diarrhea, vomiting, and constipation—which are usually mild-to-moderate and occur during dose increases.

Information: 30mg Refill Vial For Reusable Pen

Concentration

30mg

Dosage

Starting Dose: 2mg